Top in ID: CMV prevention in kidney transplant recipients; HIV rebound after suppression
Click Here to Manage Email Alerts
The FDA recently approved a new indication for Prevymis as a prophylaxis to prevent cytomegalovirus disease in high-risk adult kidney transplant patients receiving organs from CMV-seropositive donors.
Prevymis (letermovir; Merck) was first approved in 2017 to prevent CMV infection in adult CMV-seropositive patients receiving an allogeneic hematopoietic stem cell transplant. The more recent approval was based on data from a phase 3 randomized, multicenter, double-blind, active comparator-controlled noninferiority trial. It was the top story in infectious disease last week.
In another top story, researchers studied almost 4,000 people with HIV who had a sustained 2-year period of viral suppression and found that 90% continued to be virally suppressed for 2 more years. Ten percent experienced viral rebound, with risk factors being Black race, smoking and use of integrase strand transfer inhibitors.
Read these and more top stories in infectious disease below:
FDA approves letermovir to prevent CMV in kidney transplant recipients
The FDA approved letermovir for the prevention of cytomegalovirus disease in high-risk adult kidney transplant recipients, Merck announced. Read more.
HIV viral rebound rare after 2 years of consistent suppression, study finds
A study of almost 4,000 people with HIV and sustained 2-year period of viral suppression found that they were unlikely to experience viral rebound over the next 2 years, supporting treatment as prevention as an HIV prevention strategy. Read more.
BPaL a ‘game-changer’ for treatment of drug-resistant tuberculosis
BPaL shortens treatment times significantly and shows few adverse effects in patients with drug-resistant tuberculosis, according to data published in Clinical Infectious Diseases. Read more.
Xenotransplantation: Are we ready for clinical trials in humans?
For this month’s Infectious Disease News cover story, we touched base with experts in transplant medicine and transplant infectious diseases to discuss recent challenges brought on by the pandemic and the country’s organ shortage crisis. Read more.
Transplant medicine contends with organ shortage and pandemic-related disruptions
Transplant medicine and the field of transplant infectious diseases have faced numerous disruptions and challenges during the COVID-19 pandemic, according to experts. Read more.